ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,306.04
      0.02%
      US Tech 100
      18,385.60
      0.37%
      Dow Jones
      38,852.86
      -0.55%
      Brent Oil
      84.325
      1.79%
      Bitcoin
      68,386.63
      -1.45%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. PepGen Inc (PEPG)

      7. PepGen Inc (PEPG) News

      PEPG

      PepGen (PEPG)

      PepGen Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:PEPG
      DateTimeSourceHeadlineSymbolCompany
      05/17/20248:51PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PEPGPepGen Inc
      05/17/20244:33PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PEPGPepGen Inc
      05/14/20244:05PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PEPGPepGen Inc
      05/14/20244:02PMGlobeNewswire Inc.PepGen Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:PEPGPepGen Inc
      05/14/20244:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
      03/13/20244:05PMGlobeNewswire Inc.PepGen to Participate in Upcoming Investor ConferencesNASDAQ:PEPGPepGen Inc
      03/13/20247:00AMGlobeNewswire Inc.PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyNASDAQ:PEPGPepGen Inc
      03/06/20244:23PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PEPGPepGen Inc
      03/06/20244:01PMGlobeNewswire Inc.PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:PEPGPepGen Inc
      03/06/20244:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
      03/04/20247:27AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
      03/04/20247:00AMGlobeNewswire Inc.PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyNASDAQ:PEPGPepGen Inc
      03/01/20245:49PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PEPGPepGen Inc
      03/01/20245:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PEPGPepGen Inc
      03/01/20245:29PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PEPGPepGen Inc
      02/20/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
      02/20/20248:00AMGlobeNewswire Inc.PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1NASDAQ:PEPGPepGen Inc
      02/07/20244:55PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PEPGPepGen Inc
      02/07/20247:36AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
      02/07/20247:30AMGlobeNewswire Inc.PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common StockNASDAQ:PEPGPepGen Inc
      01/17/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
      01/17/20247:00AMGlobeNewswire Inc.Mary Beth DeLena Joins PepGen as General Counsel and SecretaryNASDAQ:PEPGPepGen Inc
      01/08/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
      01/08/20247:00AMGlobeNewswire Inc.PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 SkippingNASDAQ:PEPGPepGen Inc
      12/18/20238:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
      12/18/20238:00AMGlobeNewswire Inc.PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)NASDAQ:PEPGPepGen Inc
      11/15/20238:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
      11/15/20238:00AMGlobeNewswire Inc.PepGen Announces Appointment of Howard Mayer, M.D. to Board of DirectorsNASDAQ:PEPGPepGen Inc
      11/08/20238:30AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PEPGPepGen Inc
      11/08/20238:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
       Showing the most relevant articles for your search:NASDAQ:PEPG